Alimera Sciences (NASDAQ:ALIM) plummeted 25% in premarket trading after it said it filed a lawsuit against ANI ...

ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

Alimera’s lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by ...

Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), ...

Alimera Sciences, Inc. (ALIM), a biopharmaceutical company, announced on Tuesday that it has filed a lawsuit in the Delaware Court of ...

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their ...

On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

ANI Pharmaceuticals (ANIP) said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of the merger agreement, ANI acquired all of the outstanding shares of ...